276 results on '"MacMillan, Margaret L"'
Search Results
2. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice
3. FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia
4. Development of specific growth charts for children with Fanconi anemia
5. Hepatomegaly and Ascites Are Common in Immediate Post Hematopoietic Stem Cell Transplant Period in Pediatric and Adult Patients Not Diagnosed with Sinusoidal Obstruction Syndrome
6. Treatment Responsive Acute Gvhd Following Posttransplant Cyclophosphamide Based Prophylaxis: Incidence and Clinical Outcomes
7. A High Proportion of Abnormal Pulmonary Baseline Investigations in Pediatric BMT Patients: Prospective, Multi-Center Results from the Transpire Study.
8. Transpire: Lung Injury in a Longitudinal Cohort of Pediatric Hematopoietic Stem Cell Transplant Patients
9. Success and Feasibility of Multiple Breath Washout: Prospective, Multi-Center Results from the Transpire Study
10. Measurement of Respiratory System Function By Airwave Oscillometry (AOS) in a Cohort of Children Undergoing Hematopoietic Stem Cell Transplant (HSCT)
11. Breathing New Life into an Old Problem: Pulmonary Complications after Autologous Hematopoietic Stem Cell Transplant
12. Graft Vs Host Disease (GVHD) in Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients and Impact on Overall Survival: A CIBMTR Analysis
13. Mediport use as an acceptable standard for CAR T cell infusion
14. Harvest Quality, Nucleated Cell Dose and Clinical Outcomes in Bone Marrow Transplantation: A Retrospective Study
15. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy
16. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
17. Amphiregulin as monitoring biomarker for life-threatening acute graft-versushost disease: secondary analysis of two prospective clinical trials
18. Pre‐transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft‐versus‐host disease
19. Liquid Chromatography–Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment
20. Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
21. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry
22. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
23. Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease
24. Supplementary Figure S2 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
25. Supplementary Figure S3 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
26. Supplementary Figure S5 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
27. Supplementary Figure S4 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
28. Supplementary Figure S2 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
29. Supplementary Figure S6 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
30. Supplementary Figure S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
31. Supplementary Figure S5 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
32. Supplementary Figure S4 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
33. Supplementary Figure S3 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
34. Supplementary Table S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
35. Supplementary Figure S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
36. Cryopreservation for Allogeneic Hematopoetic Stem Cell Transplants Is Non-Inferior to Fresh Graft Products
37. Clinical Application of Cell-Free Next Generation Sequencing for Infections after Allogeneic Hematopoietic Cell Transplantation in Pediatric and Adult Patients: a Single Center Experience
38. Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes
39. Mediport Use As an Acceptable Standard for CAR T Cell Infusion
40. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Reduced Intensity Conditioning with Cyclophosphamide/Fludarabine/Total Body Irradiation (TBI) with Tacrolimus, MMF, and Conditional Anti Thymocyte Globulin (ATG) for the Treatment of Hematological Malignancies
41. Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increase Relapse Risk Compared to Historical Cyclosporine/ Methotrexate
42. Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
43. Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy
44. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer
45. Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis
46. Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes
47. Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
48. Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis
49. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy
50. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.